Iovance Biotherapeutics, Inc.
IOVA
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.9B
$8.87
▲ +1.90%
P/E
-12.66
Mkt Cap
$3.9B
52-Wk Range
$1.76–$9.36
52-Week Range
$1.76 - $9.36
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 295.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced cell therapy platform
- Proprietary TIL technology
- Diverse clinical pipeline
- Strategic research collaborations
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Moderate growth ahead
FDA breakthrough therapy designations
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+98.6% over 3m
Quality
Excellent
High-growth business (35% revenue growth, 116% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying IOVA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.11 vs -$0.13 consensus (+17.6% surprise). Revenue of $99.3M vs $87.8M expected (+13.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+17.6%
Revenue trend · last 8Q
—
—
—
+93%
+15%
+18%
+45%
+66%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$58.6M
$73.7M
$49.3M
$60.0M
$67.5M
$86.8M
$71.4M
$99.3M
Margins · last 8Q
Gross
54.6%
Operating
-52.3%
Profit
-47.6%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Aug 25, 2026
vs Industry
How IOVA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related